Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242670 | 0.96 | HTR6 (0.57) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL475664 | 0.86 | HPGD (0.65) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL1747995 | 0.85 | HPGD (0.64) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20242467 | 0.83 | HTR6 (0.64) | HTR6MAPTMAPK1ALDH1A1 | |
| SCHEMBL21378862 | 0.82 | HTR6 (0.47) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL21378916 | 0.81 | HTR6 (0.50) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20242252 | 0.81 | HTR6 (0.50) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20242414 | 0.81 | HPGD (0.47) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20242180 | 0.80 | HTR6 (0.45) | HTR6HPGDSMN1; SMN2MAPTMAPK1 | |
| SCHEMBL20241883 | 0.80 | HTR6 (0.48) | HTR6HPGDSMN1; SMN2MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | MICROBIOTIX, INC. (US) | 2022-10-04 | — | — | US | claimed |
| EP-3548034-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | Microbiotix, Inc. (US) | 2019-10-09 | — | — | EP | claimed |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2019-09-26 | — | — | US | claimed |
| WO-2018106667-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2018-06-14 | — | — | WO | claimed |
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | MICROBIOTIX, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3548034-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | Microbiotix, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018106667-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | NPC1L1, NPC1, GBA1 | HTR6 4498/4885HPGD 4221/4885SMN1; SMN2 1898/4885 |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | NPC1L1, NPC1, GBA1 | HTR6 4498/4885HPGD 4221/4885SMN1; SMN2 1898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.